Clinical Trial

SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by Trastuzumab，pyrotinib and Nab-Paclitaxel in second line for HER2 positive breast cancer brain metastases.
Trial Details
NCT Number NCT06975475
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Breast Cancer
Enrollment 60 participants
Start Date 2025-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-16